Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...
Medtronic plc. MDT has submitted its rechargeable, implantable sacral neuromodulation (SNM) device known as InterStim Micro neurostimulator for the FDA’s pre-market approval (PMA). This PMA supplement ...
Medtronic has submitted for FDA approval a new, rechargeable version of its 20-year-old sacral neuromodulation implant, designed to treat bowel dysfunction, overactive bladder and urinary incontinence ...
Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues SureScan™ MRI Leads Will Provide Full-Body MRI Conditional Labeling The rechargeable ...
Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary ...
Dublin-based Medtronic plc has filed a PMA supplement with the U.S. FDA for its next-generation, implantable sacral neuromodulation (SNM) device, Interstim Micro, and for its Interstim Surescan MRI ...
In November, the Food and Drug Administration (FDA) approved r-SNM, the first rechargeable sacral nerve stimulator cleared for full-body MRI scans, and sales results from the initial launch were ...
DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback